Skip to content
Screener

Jazz Pharmaceuticals JAZZ Vyxeos — Revenue from Contract with Customer, Excluding Assessed Tax

Other product segments

Xywav
$408.2M+18.4%
Epidiolex/Epidyolex
$249.8M+14.7%
Rylaze/Enrylaze
$103.7M+10.1%
Zepzelca
$101M+60.3%
Defitelio/defibrotide
$47.4M+16.5%
Modeyso
$41.4M—
High-sodium oxybate AG royalty revenue
$36.3M-25.8%
Xyrem
$31.2M-16.1%
Ziihera
$13.3M+565%
Other royalty and contract revenues
$9.76M+27.5%
Other
$2.7M-73.8%

Similar metrics at other companies

Entergy logo
ETROther revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$36.28M-41.5%
CarMax logo
KMXService revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$24.2M+24.1%
Travel + Leisure logo
TNLAncillary Revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$0-100%
Travel + Leisure logo
TNLTransaction Revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$109M-6.8%
Restaurant Brands International logo
QSRProperty revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$0-100%
Northern Trust logo
NTRSOther — Revenue from Contract with Customer, Excluding Assessed Tax
$68.6M+8.2%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.98B+165%
Enterprise value$21.71B+104%
P/S3.8×+2.3×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025
Line itemThree Months Ended March 31, 20262025
Zepzelca101.063.0
Defitelio/defibrotide47.440.7
Modeyso41.4—
Vyxeos26.629.5
Ziihera13.32.0
Oncology333.4229.4
Other12.710.3
Product sales, net1,025.3839.4

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's vyxeos — revenue from contract with customer, excluding assessed tax?
Jazz Pharmaceuticals (JAZZ) reported vyxeos — revenue from contract with customer, excluding assessed tax of $26.6M in Q1 2026.
How has Jazz Pharmaceuticals's vyxeos — revenue from contract with customer, excluding assessed tax changed year-over-year?
Jazz Pharmaceuticals's vyxeos — revenue from contract with customer, excluding assessed tax decreased by 9.8% year-over-year, from $29.5M to $26.6M.
What is the long-term trend for Jazz Pharmaceuticals's vyxeos — revenue from contract with customer, excluding assessed tax?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's vyxeos — revenue from contract with customer, excluding assessed tax has grown at a 2.3% compound annual growth rate (CAGR), from $134.06M to $146.67M.
What does vyxeos — revenue from contract with customer, excluding assessed tax mean?
This metric represents the total net revenue generated from the sale of the specific pharmaceutical product Vyxeos, a liposomal formulation used in the treatment of acute myeloid leukemia. It reflects the gross sales of the product adjusted for variable considerations such as rebates, discounts, and returns, excluding any taxes collected from customers. This figure serves as a primary indicator of the product's market adoption, clinical demand, and competitive positioning within the oncology therapeutic area.

Ask your AI about Jazz Pharmaceuticals's vyxeos — revenue from contract with customer, excluding assessed tax.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude